Related coverage linked through entity extraction aliases.
Mar 18, 2026
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Mar 10, 2026
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Feb 26, 2026
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Feb 18, 2026
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
Feb 13, 2026
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
Feb 13, 2026
The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.
